Advances in prognostic markers for colorectal cancerFootnote^*

* Lili Duan, Wanli Yang, and Xiaoqian Wang contributed equally to this work, and should be considered as the co-first authors.

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108. PubMed PMID: 25651787; eng.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. PubMed PMID: 30207593; eng.
   PubMed Web of Science ®Google Scholar
• Bae JM, Kim JH, Kang GH. Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. Arch Pathol Lab Med. 2016 May;140(5):406–412. . PubMed PMID: 27128298; eng
   PubMed Web of Science ®Google Scholar
• Bruun J, Kolberg M, Nesland JM, et al. Prognostic significance of beta-Catenin, E-Cadherin, and SOX9 in colorectal cancer: results from a large population-representative series. Front Oncol. 2014;4:118. . PubMed PMID: 24904831; PubMed Central PMCID: PMCPMC4033250. eng
   PubMedGoogle Scholar
• Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017 Sep;14(9):531–548. PubMed PMID: 28252003; eng.
   PubMed Web of Science ®Google Scholar
• Mader S, Pantel K. Liquid biopsy: current status and future perspectives. Oncol Res Treat. 2017;40(7–8):404–408. . PubMed PMID: 28693023; eng
   PubMed Web of Science ®Google Scholar
• Normanno N, Cervantes A, Ciardiello F, et al. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios. Cancer Treat Rev. 2018 Jul 18; 70:1–8. PubMed PMID: 30053724; eng.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011 Jun;11(6):426–437. . PubMed PMID: 21562580; eng
   PubMed Web of Science ®Google Scholar
• Spindler KL, Pallisgaard N, Andersen RF, et al. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PloS one. 2015;10(4):e0108247. . PubMed PMID: 25875772; PubMed Central PMCID: PMCPMC4395277. eng
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci trans med. 2014 Feb 19;6(224):224ra24. PubMed PMID: 24553385; PubMed Central PMCID: PMCPMC4017867. eng.
   PubMed Web of Science ®Google Scholar
• Spindler KL, Appelt AL, Pallisgaard N, et al. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer. 2014 Dec 15;135(12):2984–2991. PubMed PMID: 24798213; eng.
   PubMed Web of Science ®Google Scholar
• Philipp AB, Stieber P, Nagel D, et al. Prognostic role of methylated free circulating DNA in colorectal cancer. Int J Cancer. 2012 Nov 15;131(10):2308–2319. PubMed PMID: 22362391; eng.
   PubMed Web of Science ®Google Scholar
• El Messaoudi S, Mouliere F, Du Manoir S, et al. Circulating DNA as a strong multimarker prognostic tool for metastatic colorectal cancer patient management care. Clin Cancer Res. 2016 Jun 15;22(12):3067–3077. 10.1158/1078-0432.Ccr-15-0297. PubMed PMID: 26847055; eng.
   PubMed Web of Science ®Google Scholar
• Spindler KG, Boysen AK, Pallisgard N, et al. Cell-free DNA in metastatic colorectal cancer: a systematic review and meta-analysis. Oncologist. 2017 Sep;22(9):1049–1055. PubMed PMID: 28778958; PubMed Central PMCID: PMCPMC5599199. eng.
   PubMed Web of Science ®Google Scholar
• Myint NNM, Verma AM, Fernandez-Garcia D, et al. Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. Cell Death Dis. 2018 Aug 30;9(9):894. PubMed PMID: 30166531; PubMed Central PMCID: PMCPMC6117318. eng.
   PubMedGoogle Scholar
• Matikas A, Voutsina A, Trypaki M, et al. Role of circulating free DNA in colorectal cancer. World J Gastrointest Oncol. 2016 Dec 15;8(12):810–818. PubMed PMID: 28035251; PubMed Central PMCID: PMCPMC5156847. eng.
   PubMed Web of Science ®Google Scholar
• Engell HC. [Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation]. Ugeskr Laeger. 1955 Jun 23;117(25):822–823. PubMed PMID: 13247497; dan
   PubMedGoogle Scholar
• Yang C, Zou K, Zheng L, et al. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review. BMC Cancer. 2017 Nov 7;17(1):725. PubMed PMID: 29115932; PubMed Central PMCID: PMCPMC5688806.
   PubMedGoogle Scholar
• Groot Koerkamp B, Rahbari NN, Buchler MW, et al. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013 Jul;20(7):2156–2165. PubMed PMID: 23456317; eng.
   PubMed Web of Science ®Google Scholar
• Zhe X, Cher ML, Bonfil RD. Circulating tumor cells: finding the needle in the haystack. Am J Cancer Res. 2011;1(6):740–751. PubMed PMID: 22016824; PubMed Central PMCID: PMCPMC3195935. eng
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010 Jun;138(6):2073–2087.e3. PubMed PMID: 20420947; PubMed Central PMCID: PMCPMC3037515. eng.
   PubMed Web of Science ®Google Scholar
• Boland CR, Thibodeau SN, Hamilton SR, et al. A National cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 Nov 15;58(22):5248–5257. PubMed PMID: 9823339; eng
   PubMed Web of Science ®Google Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005 Jan 20;23(3):609–618. PubMed PMID: 15659508; eng.
   PubMed Web of Science ®Google Scholar
• Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003 Jul 17;349(3):247–257. PubMed PMID: 12867608; PubMed Central PMCID: PMCPMC3584639. eng.
   PubMed Web of Science ®Google Scholar
• Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National cancer Institute-National surgical adjuvant breast and bowel project collaborative study. J Clin Oncol. 2007 Mar 1;25(7):767–772. PubMed PMID: 17228023; eng.
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917–923. PubMed PMID: 11535541; eng
   PubMed Web of Science ®Google Scholar
• Micu BV, Andercou O, Vesa SC, et al. The prognostic role of microsatellite instability in colorectal cancer patients. Ann Ital Chir. 2017;6:425–432. PubMed PMID: 28874631; eng
   PubMedGoogle Scholar
• Romiti A, Rulli E, Pilozzi E, et al. Exploring the prognostic role of microsatellite instability in patients with stage II colorectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer. 2017 Jun;16(2):e55–e59. PubMed PMID: 27670891; eng.
   PubMed Web of Science ®Google Scholar
• Toh JWT, de Souza P, Lim SH, et al. The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy. Clin Colorectal Cancer. 2016 Dec;15(4):285–291. PubMed PMID: 27553906; eng.
   PubMed Web of Science ®Google Scholar
• Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015 Jul;16(7):30. . PubMed PMID: 26031544; PubMed Central PMCID: PMCPMC4594190. eng
   PubMed Web of Science ®Google Scholar
• Lagna G, Hata A, Hemmati-Brivanlou A, et al. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature. 1996 Oct 31;383(6603):832–836. PubMed PMID: 8893010; eng.
   PubMed Web of Science ®Google Scholar
• Drabsch Y, Ten Dijke P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012 Dec;31(3–4):553–568. . PubMed PMID: 22714591; eng
   PubMed Web of Science ®Google Scholar
• Yu J, Wu WK, Li X, et al. Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut. 2015 Apr;64(4):636–645. PubMed PMID: 24951259; PubMed Central PMCID: PMCPMC4392212. eng.
   PubMed Web of Science ®Google Scholar
• Voorneveld PW, Jacobs RJ, Kodach LL, et al. A meta-analysis of SMAD4 immunohistochemistry as a prognostic marker in colorectal cancer. Transl Oncol. 2015 Feb;8(1):18–24. PubMed PMID: 25749173; PubMed Central PMCID: PMCPMC4350636. eng.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Cloyd JM, Vicente D, et al. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. Eur J Surg Oncol. 2018 May;44(5):684–692. PubMed PMID: 29551247; eng.
   PubMed Web of Science ®Google Scholar
• Oyanagi H, Shimada Y, Nagahashi M, et al. SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer. Histopathology. 2019 Jan 12. DOI:10.1111/his.13805. PubMed PMID: 30636020; eng.
   PubMedGoogle Scholar
• Mehrvarz Sarshekeh A, Advani S, Overman MJ, et al. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PloS one. 2017;12(3):e0173345. . PubMed PMID: 28267766; PubMed Central PMCID: PMCPMC5340382. eng
   PubMed Web of Science ®Google Scholar
• Mei Z, Shao YW, Lin P, et al. SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients. BMC Cancer. 2018 Apr 27;18(1):479. 10.1186/s12885-018-4298-5. PubMed PMID: 29703253; PubMed Central PMCID: PMCPMC5921972. eng
   PubMedGoogle Scholar
• Kozak MM, von Eyben R, Pai J, et al. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer. J Clin Pathol. 2015 May;68(5):341–345. PubMed PMID: 25681512; eng.
   PubMed Web of Science ®Google Scholar
• Matallanas D, Birtwistle M, Romano D, et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer. 2011 Mar;2(3):232–260. 10.1177/1947601911407323. PubMed PMID: 21779496; PubMed Central PMCID: PMCPMC3128629. eng
   PubMedGoogle Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 Jul 22;351(4):337–345. PubMed PMID: 15269313; eng.
   PubMed Web of Science ®Google Scholar
• de Cuba EM, Snaebjornsson P, Heideman DA, et al. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. Int J Cancer. 2016 Mar 1;138(5):1139–1145. PubMed PMID: 26376292.
   PubMed Web of Science ®Google Scholar
• Kadowaki S, Kakuta M, Takahashi S, et al. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol. 2015 Jan 28;21(4):1275–1283. PubMed PMID: 25632202; PubMed Central PMCID: PMCPMC4306173. eng.
   PubMed Web of Science ®Google Scholar
• Nannini M, Pantaleo MA, Maleddu A, et al. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009 May;35(3):201–209. PubMed PMID: 19081199; eng.
   PubMed Web of Science ®Google Scholar
• Nguyen MN, Choi TG, Nguyen DT, et al. CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer. Oncotarget. 2015 Oct 13;6(31):31674–31692. PubMed PMID: 26397224; PubMed Central PMCID: PMCPMC4741632. eng.
   PubMedGoogle Scholar
• Park YY, Lee SS, Lim JY, et al. Comparison of prognostic genomic predictors in colorectal cancer. PloS one. 2013;8(4):e60778. . PubMed PMID: 23626670; PubMed Central PMCID: PMCPMC3634034. eng
   PubMed Web of Science ®Google Scholar
• Chang W, Gao X, Han Y, et al. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut. 2014 Sep;63(9):1457–1467. PubMed PMID: 24173294; eng.
   PubMed Web of Science ®Google Scholar
• Alnabulsi A, Murray GI, Integrative analysis of the colorectal cancer proteome: potential clinical impact. Expert Rev Proteomics. 2016 Sep 19:1–11. PubMed PMID: 27598033; eng. DOI:10.1080/14789450.2016.1233062.
   PubMed Web of Science ®Google Scholar
• McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999 Jan;79(2):191–203. . PubMed PMID: 9888457; PubMed Central PMCID: PMCPMC2362193. eng
   PubMed Web of Science ®Google Scholar
• Wang J, Wang X, Yu F, et al. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients. Int J Clin Exp Pathol. 2015;8(11):14853–14863. PubMed PMID: 26823815; PubMed Central PMCID: PMCPMC4713601. eng
   PubMed Web of Science ®Google Scholar
• Li W, Zhang G, Wang HL, et al. Analysis of expression of cyclin E, p27kip1 and Ki67 protein in colorectal cancer tissues and its value for diagnosis, treatment and prognosis of disease. Eur Rev Med Pharmacol Sci. 2016 Dec;20(23):4874–4879. PubMed PMID: 27981549; eng
   PubMed Web of Science ®Google Scholar
• Lorentz O, Duluc I, Arcangelis AD, et al. Key role of the Cdx2 homeobox gene in extracellular matrix-mediated intestinal cell differentiation. J Cell Biol. 1997 Dec 15;139(6):1553–1565. PubMed PMID: 9396760; PubMed Central PMCID: PMCPMC2132620. eng
   PubMed Web of Science ®Google Scholar
• Bae JM, Lee TH, Cho NY, et al. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol. 2015 Feb 7;21(5):1457–1467. PubMed PMID: 25663765; PubMed Central PMCID: PMCPMC4316088.
   PubMed Web of Science ®Google Scholar
• Graule J, Uth K, Fischer E, et al. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clin Epigenetics. 2018 Sep 26;10(1):120. 10.1186/s13148-018-0548-2. PubMed PMID: 30257705; eng
   PubMedGoogle Scholar
• Maki H, Sekiguchi M. MutT protein specifically hydrolyses a potent mutagenic substrate for DNA synthesis. Nature. 1992 Jan 16;355(6357):273–275. PubMed PMID: 1309939; eng.
   PubMed Web of Science ®Google Scholar
• Li J, Yang CC, Tian XY, et al. MutT-related proteins are novel progression and prognostic markers for colorectal cancer. Oncotarget. 2017 Dec 1;8(62):105714–105726. PubMed PMID: 29285286; PubMed Central PMCID: PMCPMC5739673. eng.
   PubMedGoogle Scholar
• Peng J, Qi S, Wang P, et al. Diagnosis and prognostic significance of c-Met in cervical cancer: a meta-analysis. Dis Markers. 2016;2016:6594016. . PubMed PMID: 27069297; PubMed Central PMCID: PMCPMC4812361. eng
   PubMedGoogle Scholar
• Zeng Z, Weiser MR, D’Alessio M, et al. Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Clin Exp Metastasis. 2004;21(5):409–417. PubMed PMID: 15672865; eng
   PubMed Web of Science ®Google Scholar
• Fujita S, Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol. 1997 Dec;27(6):378–383. PubMed PMID: 9437998; eng
   PubMed Web of Science ®Google Scholar
• Shoji H, Yamada Y, Taniguchi H, et al. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci. 2014 Aug;105(8):1002–1007. PubMed PMID: 24863535; PubMed Central PMCID: PMCPMC4317860. eng.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yu XF, Zou J, et al. Prognostic value of c-Met in colorectal cancer: a meta-analysis. World J Gastroenterol. 2015 Mar 28;21(12):3706–3710. PubMed PMID: 25834339; PubMed Central PMCID: PMCPMC4375596.
   PubMed Web of Science ®Google Scholar
• Gao H, Guan M, Sun Z, et al. High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis. Tumour Biol. 2015 Feb;36(2):515–520. PubMed PMID: 25636446; eng.
   PubMedGoogle Scholar
• Li T, Kon N, Jiang L, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012 Jun 8;149(6):1269–1283. PubMed PMID: 22682249; PubMed Central PMCID: PMCPMC3688046.
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014 Mar 17;25(3):304–317. PubMed PMID: 24651012; PubMed Central PMCID: PMCPMC3970583. eng.
   PubMed Web of Science ®Google Scholar
• Wang P, Liang J, Wang Z, et al. The prognostic value of p53 positive in colorectal cancer: a retrospective cohort study. Tumour Biol. 2017 May;39(5):1010428317703651. PubMed PMID: 28468582.
   Google Scholar
• Liu BW, Liu Y, Liu JR, et al. Prognostic effect of p53 expression in patients with completely resected colorectal cancer. Tumour Biol. 2014 Oct;35(10):9893–9896. PubMed PMID: 24993094; eng.
   PubMedGoogle Scholar
• Peng Q, Zhang X, Min M, et al. The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2017 Jul 4;8(27):44893–44909. PubMed PMID: 28415652; PubMed Central PMCID: PMCPMC5546529. eng.
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215–233. PubMed PMID: 19167326; PubMed Central PMCID: PMCPMC3794896. eng.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314. PubMed PMID: 24079833; PubMed Central PMCID: PMCPMC4009396. eng.
   PubMed Web of Science ®Google Scholar
• Yan S, Cao Y, Mao A. MicroRNAs in colorectal cancer: potential biomarkers and therapeutic targets. Front Biosci (Landmark Ed). 2015 Jun 1;20:1092–1103. PubMed PMID: 25961547; eng.
   PubMed Web of Science ®Google Scholar
• Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010 Apr;10(3):297–308. . PubMed PMID: 20370587; eng
   PubMed Web of Science ®Google Scholar
• Nana-Sinkam P, Croce CM. MicroRNAs in diagnosis and prognosis in cancer: what does the future hold? Pharmacogenomics. 2010 May;11(5):667–669. . PubMed PMID: 20415558; eng
   PubMed Web of Science ®Google Scholar
• Ren A, Dong Y, Tsoi H, et al. Detection of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol Sci. 2015 Jan 27;16(2):2810–2823. PubMed PMID: 25633103; PubMed Central PMCID: PMCPMC4346866. eng.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liu H, Jin W, et al. Tissue microRNA-21 expression predicted recurrence and poor survival in patients with colorectal cancer - a meta-analysis. Onco Targets Ther. 2016:9:2615–2624. PubMed PMID: 27226723; PubMed Central PMCID: PMCPMC4863680. eng.
   PubMed Web of Science ®Google Scholar
• Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21098–21103. PubMed PMID: 21078976; PubMed Central PMCID: PMCPMC3000294. eng.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liu S, Tian L, et al. miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. Oncotarget. 2015 Nov 10;6(35):38139–38150. PubMed PMID: 26497367; PubMed Central PMCID: PMCPMC4741989. eng.
   PubMedGoogle Scholar
• Wang MJ, Li Y, Wang R, et al. Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer. Int J Colorectal Dis. 2013 Feb;28(2):183–189. PubMed PMID: 22885837; eng.
   PubMed Web of Science ®Google Scholar
• Caiazza C, Mallardo M. The roles of miR-25 and its targeted genes in development of human cancer. Microrna. 2016;5(2):113–119.
   PubMedGoogle Scholar
• Li X, Yang C, Wang X, et al. The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis. Med Oncol. 2014 Jan;31(1):781. PubMed PMID: 24293092.
   PubMed Web of Science ®Google Scholar
• Ma H, Pan JS, Jin LX, et al. MicroRNA-17~92 inhibits colorectal cancer progression by targeting angiogenesis. Cancer Lett. 2016 Jul 1;376(2):293–302. PubMed PMID: 27080303; eng.
   PubMed Web of Science ®Google Scholar
• Yu G, Tang J-Q, Tian M-L, et al. Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer. J Surg Oncol. 2012 Sep;106(3):232–237. PubMed PMID: WOS:000307165600004.
   PubMed Web of Science ®Google Scholar
• Fang L, Li H, Wang L, et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014 May 30;5(10):2974–2987. PubMed PMID: 24912422; PubMed Central PMCID: PMCPMC4102784. eng.
   PubMedGoogle Scholar
• Yang MH, Yu J, Chen N, et al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PloS one. 2013;8(12):e85353. . PubMed PMID: 24386467; PubMed Central PMCID: PMCPMC3875556. eng
   PubMed Web of Science ®Google Scholar
• Yuan Z, Baker K, Redman MW, et al. Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer. Br J Cancer. 2017 Oct 10;117(8):1202–1210. PubMed PMID: 28809863; PubMed Central PMCID: PMCPMC5674097. eng.
   PubMed Web of Science ®Google Scholar
• Igarashi H, Kurihara H, Mitsuhashi K, et al. Association of MicroRNA-31-5p with clinical efficacy of Anti-EGFR therapy in patients with metastatic colorectal cancer. Ann Surg Oncol. 2015 Aug;22(8):2640–2648. PubMed PMID: 25472647; eng.
   PubMed Web of Science ®Google Scholar
• Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998 May 15;58(10):2170–2175. PubMed PMID: 9605762; eng
   PubMed Web of Science ®Google Scholar
• Liu B, Liu Y, Zhao L, et al. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. Mol Carcinog. 2017 Dec;56(12):2669–2680. PubMed PMID: 28767179; eng.
   PubMed Web of Science ®Google Scholar
• S L, X R, Y L, et al. miR-182 and miR-135b mediate the tumorigenesis and invasiveness of colorectal cancer cells via targeting ST6GALNAC2 and PI3K/AKT pathway. Digestive Dis Sci. 2017;62(12):3447–3459.
   PubMed Web of Science ®Google Scholar
• Liu H, Du L, Wen Z, et al. Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int J Colorectal Dis. 2013 May;28(5):697–703. PubMed PMID: 23474644; eng.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang M-H, Wang X-Y, et al. Increased expression of miRNA-182 in colorectal carcinoma: an independent and tissue-specific prognostic factor. Int J Clin Exp Pathol. 2014;7(6):3498–3503. PubMed PMID: WOS:000338770500090
   PubMed Web of Science ®Google Scholar
• Piriyapongsa J, Jordan IK. A family of human MicroRNA genes from miniature inverted-repeat transposable elements. PloS one. 2007 Feb 14;2(2). PubMed PMID: WOS:000207444400004. DOI:10.1371/journal.pone.0000203
   PubMed Web of Science ®Google Scholar
• Yan S, Han B, Gao S, et al. Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget. 2017 Sep 1;8(36):60149–60158. PubMed PMID: 28947960; PubMed Central PMCID: PMCPMC5601128. eng.
   PubMedGoogle Scholar
• Peng ZY, Gu RH, Yan B. Downregulation of exosome-encapsulated miR-548c-5p is associated with poor prognosis in colorectal cancer. J Cell Biochem. 2018 Sep 1. DOI:10.1002/jcb.27291. PubMed PMID: 30171732; eng.
   Web of Science ®Google Scholar
• Cui BH, Hong X. miR-6852 serves as a prognostic biomarker in colorectal cancer and inhibits tumor growth and metastasis by targeting TCF7. Exp Ther Med. 2018 Aug;16(2):879–885. . PubMed PMID: 30116340; PubMed Central PMCID: PMCPMC6090274. eng
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology. 2015 Oct;149(5):1204-+. PubMed PMID: WOS:000365087700009.
   PubMed Web of Science ®Google Scholar
• Vedeld HM, Merok M, Jeanmougin M, et al. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. Int J Cancer. 2017 Sep 1;141(5):967–976. PubMed PMID: 28542846; PubMed Central PMCID: PMCPMC5518206.
   PubMed Web of Science ®Google Scholar
• Cha Y, Kim KJ, Han SW, et al. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. Br J Cancer. 2016 Jul 12;115(2):164–171. PubMed PMID: 27310704; PubMed Central PMCID: PMCPMC4947699. eng.
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001 Feb 15;409(6822):860–921. PubMed PMID: MEDLINE:11237011.
   PubMed Web of Science ®Google Scholar
• Meiboom M, Murua Escobar H, Pentimalli F, et al. A 3.4-kbp transcript of ZNF331 is solely expressed in follicular thyroid adenomas. Cytogenet Genome Res. 2003;101(2):113–117. . PubMed PMID: MEDLINE:14610350
   PubMed Web of Science ®Google Scholar
• Wang Y, He T, Herman JG, et al. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth. Clin Epigenetics. 2017;9:115. . PubMed PMID: 29075358; PubMed Central PMCID: PMCPMC5648453
   PubMed Web of Science ®Google Scholar
• Vedeld HM, Nesbakken A, Lothe RA, et al. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin Epigenetics. 2018;10:70. . PubMed PMID: 29854011; PubMed Central PMCID: PMCPMC5975481. eng
   PubMed Web of Science ®Google Scholar
• Inamura K, Yamauchi M, Nishihara R, et al. Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst. 2014 Sep;106(9). PubMed PMID: 25190725; PubMed Central PMCID: PMCPMC4161997. eng. DOI:10.1093/jnci/dju195.
   PubMedGoogle Scholar
• Kaneko M, Kotake M, Bando H, et al. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer. Bmc Cancer. 2016;Dec 12;16. PubMed PMID: WOS:000390474100001. DOI:10.1186/s12885-016-2984-8.
   PubMed Web of Science ®Google Scholar
• Ye D, Jiang D, Li Y, et al. The role of LINE-1 methylation in predicting survival among colorectal cancer patients: a meta-analysis. Int J Clin Oncol. 2017 Aug;22(4):749–757. PubMed PMID: WOS:000406689300018.
   PubMed Web of Science ®Google Scholar
• Grizzi F, Basso G, Borroni EM, et al. Evolving notions on immune response in colorectal cancer and their implications for biomarker development. Inflammation Res. 2018 May;67(5):375–389. 10.1007/s00011-017-1128-1. PubMed PMID: 29322204; eng
   PubMed Web of Science ®Google Scholar
• Herrera M, Herrera A, Dominguez G, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013 Apr;104(4):437–444. PubMed PMID: 23298232; eng.
   PubMed Web of Science ®Google Scholar
• Cabrero-de Las Heras S, Martinez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol. 2018 Nov 14;24(42):4738–4749. PubMed PMID: 30479461; PubMed Central PMCID: PMCPMC6235799. eng.
   PubMed Web of Science ®Google Scholar
• Hu X, Li YQ, Li QG, et al. ITGAE defines CD8+ tumor-infiltrating lymphocytes predicting a better prognostic survival in colorectal cancer. EBioMedicine. 2018 Sep;35:178–188. PubMed PMID: 30100393; PubMed Central PMCID: PMCPMC6154785. eng.
   PubMed Web of Science ®Google Scholar
• Li Y, Liang L, Dai W, et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 2016 Aug 24;15(1):55. 10.1186/s12943-016-0539-x. PubMed PMID: 27552968; PubMed Central PMCID: PMCPMC4995750. eng
   PubMed Web of Science ®Google Scholar
• Basile D, Garattini SK, Bonotto M, et al. Immunotherapy for colorectal cancer: where are we heading? Expert Opin Biol Ther. 2017 Jun;17(6):709–721. PubMed PMID: 28375039; eng.
   PubMed Web of Science ®Google Scholar
• Tilg H, Adolph TE, Gerner RR, et al. The intestinal microbiota in colorectal cancer. Cancer Cell. 2018 Jun 11;33(6):954–964. PubMed PMID: 29657127; eng.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cai S, Ma Y. Association between Fusobacterium nucleatum and colorectal cancer: progress and future directions. J Cancer. 2018;9(9):1652–1659. . PubMed PMID: 29760804; PubMed Central PMCID: PMCPMC5950595. eng
   PubMed Web of Science ®Google Scholar
• Morgillo F, Dallio M, Della Corte CM, et al. Carcinogenesis as a result of multiple inflammatory and oxidative hits: a comprehensive review from tumor microenvironment to Gut microbiota. Neoplasia (New York, NY). 2018 Jul;20(7):721–733. PubMed PMID: 29859426; PubMed Central PMCID: PMCPMC6014569. eng.
   PubMed Web of Science ®Google Scholar
• Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget. 2016 Jul 19;7(29):46158–46172. PubMed PMID: 27323816; PubMed Central PMCID: PMCPMC5216788. eng.
   PubMedGoogle Scholar
• Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011 Mar;60(3):397–411. PubMed PMID: 21036793; PubMed Central PMCID: PMCPMC3040598. eng.
   PubMed Web of Science ®Google Scholar
• Ogino S, Nowak JA, Hamada T, et al. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol. 2019 Jan;24(14):83–103. PubMed PMID: 30125150; PubMed Central PMCID: PMCPMC6345592. eng.
   PubMed Web of Science ®Google Scholar
• Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf). 2015 Nov;3(4):269–276. . PubMed PMID: 26337942; PubMed Central PMCID: PMCPMC4650976. eng
   PubMed Web of Science ®Google Scholar
• Ogino S, Lochhead P, Giovannucci E, et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014 Jun 5;33(23):2949–2955. PubMed PMID: 23792451; PubMed Central PMCID: PMCPMC3818472. eng.
   PubMed Web of Science ®Google Scholar
• Yang W, Liu L, Masugi Y, et al. Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). Gut. 2018 Aug;67(8):1475–1483. PubMed PMID: 28676564; PubMed Central PMCID: PMCPMC5754263. eng.
   PubMed Web of Science ®Google Scholar
• Momen-Heravi F, Masugi Y, Qian ZR, et al. Tumor expression of calcium sensing receptor and colorectal cancer survival: results from the nurses’ health study and health professionals follow-up study. Int J Cancer. 2017 Dec 15;141(12):2471–2479. PubMed PMID: 28856682; PubMed Central PMCID: PMCPMC5768412. eng.
   PubMed Web of Science ®Google Scholar